955 Chesterbrook Boulevard
Suite 110
Chesterbrook, PA 19087
United States
610 354 8840
https://www.trevena.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 23
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Ms. Carrie L. Bourdow | President, CEO & Chairman | 1M | S.O. | 1963 |
Mr. Barry Shin | Executive VP, COO & CFO | 670,02k | S.O. | 1972 |
Dr. Mark A. Demitrack M.D. | Senior VP & Chief Medical Officer | 690,32k | S.O. | 1958 |
Dr. Howard A. Rockman M.D. | Scientific Founder, Consultant and Member of Scientific Advisory Board | S.O. | S.O. | S.O. |
Mr. Joel Solomon | VP, General Counsel & Chief Compliance Officer | S.O. | S.O. | S.O. |
Mr. Michael Catalano | Vice President of Marketing | S.O. | S.O. | S.O. |
Mr. Robert T. Yoder | Senior VP, Chief Business Officer & Head of Commercial Operations | 490,64k | S.O. | 1966 |
Ms. Patricia M. Drake | Senior VP & Chief Commercial Officer | S.O. | S.O. | 1966 |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
L’ISS Governance QualityScore de Trevena, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..